Breaking News

Tweet TWEET

RBCC to Increase Investment in 3D Bioprinting Innovation

  RBCC to Increase Investment in 3D Bioprinting Innovation

Business Wire

MIRAMAR BEACH, Fla. -- March 25, 2014

As demand for new cellular research innovations continues to soar worldwide,
Rainbow Biosciences, the biotechnology division of Rainbow Coral Corp. (OTCBB:
RBCC), is increasing its investment in the marketing and development of a
breakthrough 3D bioprinting technology.

The company announced today that it is in final negotiations to further its
involvement in Nano 3D Biosciences (n3D), a cutting-edge technology company
drawing international interest with its revolutionary BiO Assay, the first
commercially available 3D bioprinting system designed for high throughput and
high-content drug screening.

RBCC took an equity interest in n3D in 2012, not long after the companies
formed a joint venture to market and develop new technologies for the
fast-growing, global biotechnology marketplace. Now, the company plans to
double down on that investment position as n3D becomes a leading stakeholder
in an industry forecast to be worth $10 billion by 2030.

“We’re proud of our partnership with n3D, and we look forward to helping
deliver the amazing potential of the BiO Assay to researchers all over the
world,” said RBCC CEO Kimberly Palmer.

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop
new medical and research technology innovations to compete alongside companies
such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and
Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity
interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visitwww.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO
info@rainbowbiosciences.com
 
Press spacebar to pause and continue. Press esc to stop.